Online inquiry

IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15901MR)

This product GTTS-WQ15901MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15901MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3042MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ8999MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ15482MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ1326MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ2349MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ4615MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ5428MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ12462MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NKTR-214
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW